The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors

Human Gene Therapy

Volumn 14, Issue 7, 2003, Pages 627-643

  Liu, Qiang ^a   Zaiss, Anne K ^a   Colarusso, Pina ^b   Patel, Kamala ^b   Haljan, Gregory ^a   Wickham, Thomas J ^c   Muruve, Daniel A ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GREEN FLUORESCENT PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEPATITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; KUPFFER CELL; LIVER SINUSOID; MOUSE; NONHUMAN; VIRUS CAPSID; WILD TYPE;

ADENOVIRIDAE; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CAPSID; CELL MOVEMENT; CHEMOKINES; CYTOKINES; DEFECTIVE VIRUSES; ENDOTHELIUM, VASCULAR; GENETIC VECTORS; HUMANS; KUPFFER CELLS; LIVER; MICE; MICE, INBRED DBA; NEUTROPHILS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MIRIDAE;

EID: 0038069517     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403321618146     Document Type: Article

References (49)

1. ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
2. BALTER, M. (2000). Gene therapy on trial. Science 288, 951-957.
3. BECKER, T.C., NOEL, R.J., COATS, W.S., GOMEZ-FOIX, A.M., ALAM, T., GERARD, R.D., and NEWGARD, C.B. (1994). Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43, 161-189.
4. BORGLAND, S.L., BOWEN, G.P., WONG, N.C., LIBERMANN, T.A., and MURUVE, D.A. (2000). Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-κB. J. Virol. 74, 3941-3947.
5. BOWEN, G.P., BORGLAND, S.L., LAM, M., LIBERMANN, T.A., WONG, N.C., and MURUVE, D.A. (2002). Adenovirus vector-induced inflammation: Capsid-dependent induction of the C-C chemokine RANTES requires NF-κB. Hum. Gene Ther. 13, 367-379.
6. BRUDER, J.T., and KOVESDI, I. (1997). Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J. Virol. 71, 398-404.
7. COTTEN, M., WAGNER, E., ZATLOUKAL, K., PHILLIPS, S., CURIEL, D.T., and BIRNSTIEL, M.L. (1992). High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci. U.S.A. 89, 6094-6098.
8. COTTEN, M., SALTIK, M., KURSA, M., WAGNER, E., MAASS, G., and BIRNSTIEL, M.L (1994). Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology 205, 254-261.
9. DECHECCHI, M.C., MELOTTI, P., BONIZZATO, A., SANTACAT-TERINA, M., CHILOSI, M., and CABRINI, G. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75, 8772-8780.
10. DECKER, T., and LOHMANN-MATFHES, M.L. (1988). A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115, 61-69.
11. DONG, C, WILSON, J.E., WINTERS, G.L., and MCMANUS, B.M. (1996). Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab. Invest. 74, 921-931.
12. EINFELD, D.A., SCHROEDER, R., ROELVINK, P.W., LIZONOVA, A., KING, C.R., KOVESDI, I., and WICKHAM, T.J. (2001). Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75, 11284-11291.
13. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5, 1217-1229.
14. FEARON, D.T., and LOCKSLEY, R.M. (1996). The instructive role of innate immunity in the acquired immune response. Science 272, 50-53.
15. GREBER, U.F., WILLETTS, M., WEBSTER, P., and HELENIUS, A. (1993). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75, 477-486.
16. GUIDOTTI, L.G., and CHISARI, F.V. (2001). Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65-91.
17. HANSON, C.V., SHEN, C.K., and HEARST, J.E. (1976). Cross-linking of DNA in situ as a probe for chromatin structure. Science 193, 62-64.
18. HARDONK, M.J., DIJKHUIS, F.W., HULSTAERT, C.E., and KOUDSTAAL, J. (1992). Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. J. Leukoc. Biol. 52, 296-302.
19. HIGGINBOTHAM, J.N., SETH, P., BLAESE, R.M., and RAMSEY, W.J. (2002). The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. 13, 129-141.
20. HITT, M.M., and GRAHAM, F.L. (2000). Adenovirus vectors for human gene therapy. Adv. Virus Res. 55, 479-505.
21. INMAN, R.B., and SCHNOS, M. (1987). Electron microscopic identification of supercoiled regions in complex DNA structures. J. Mol. Biol. 193, 377-384.
22. KAFRI, T., MORGAN, D., KRAHL, T., SARVETNICK, N., SHERMAN, L., and VERMA, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95, 11377-11382.
23. KASS-EISLER, A., FALCK-PEDERSEN, E., ELFENBEIN, D.H., ALVIRA, M., BUTTRICK, P.M., and LEINWAND, L.A. (1994). The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1, 395-402.
24. KIM, I.H., JOZKOWICZ, A., PIEDRA, P.A., OKA, K., and CHAN, L. (2001). Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. U.S.A. 98, 13282-13287.
25. KUBES, P., JUTILA, M., and PAYNE, D. (1995). Therapeutic potential of inhibiting leukocyte rolling in ischemia/repeffusion. J. Clin. Invest. 95, 2510-2519.
26. KUZMIN, A.I., FINEGOLD, M.J., and EISENSMITH, R.C. (1997). Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther. 4, 309-316.
27. LEOPOLD, P.L., FERRIS, B., GRINBERG, I., WORGALL, S., HACKETT, N.R., and CRYSTAL, R.G. (1998). Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum. Gene Ther. 9, 367-378.
28. LI, Y., MURUVE, D.A., COLLINS, R.G., LEE, S.S., and KUBES, P. (2002). The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur. J. Immunol. 32, 3443-3452.
29. LIEBER, A., HE, C.Y., MEUSE, L., SCHOWALTER, D., KIRILLOVA, I., WINTHER, B., and KAY, M.A. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807.
30. LO, D., FENG, L., LI, L., CARSON, M.J., CROWLEY, M., PAUZA, M., NGUYEN, A., and REILLY, C.R. (1999). Integrating innate and adaptive immunity in the whole animal. Immunol. Rev. 169, 225-239.
31. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
32. MOSHER, B., DEAN, R., HARKEMA, J., REMICK, D., PALMA, J., and CROCKETT, E. (2001). Inhibition of Kupffer cells reduced CXC chemokine production and liver injury. J. Surg. Res. 99, 201-210.
33. MURUVE, D.A., BARNES, M.J., STILLMAN, I.E., and LIBERMANN, T.A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976.
34. NACHMAN, P.H., HOGAN, S.L., JENNETTE, J.C., and FALK, R.J. (1996). Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7, 33-39.
35. O'NEAL, W.K., ZHOU, H., MORRAL, N., LANGSTON, C., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., and BEAUDET, A.L. (2000). Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med. 6, 179-195.
36. ROELVINK, P.W., MI LEE, G., EINFELD, D.A., KOVESDI, I., and WICKHAM, T.J. (1999). Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing Adenoviridae. Science 286, 1568-1571.
37. SCHNELL, M.A., ZHANG, Y., TAZELAAR, J., GAO, G.P., YU, Q.C., QIAN, R., CHEN, S.J., VARNAVSKI, A.N., LECLAIR, C., RAPER, S.E., and WILSON, J.M. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708-722.
38. SCHUMANN, J., WOLF, D., PAHL, A., BRUNE, K., PAPADOPOULOS, T., VAN ROOIJEN, N., and TIEGS, G. (2000). Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am. J. Pathol. 157, 1671-1683.
39. SMITH, T., IDAMAKANTI, N., KYLEFJORD, H., ROLLENCE, M., KING, L., KALOSS, M., KALEKO, M., and STEVENSON, S.C. (2002). In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol. Ther. 5, 770-779.
40. SUOMALAINEN, M., NAKANO, M.Y., BOUCKE, K., KELLER, S., and GREBER, U.F. (2001). Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J. 20, 1310-1319.
41. TAO, N., GAO, G.P., PARR, M., JOHNSTON, J., BARADET, T., WILSON, J.M., BARSOUM, J., and FAWELL, S.E. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3, 28-35.
42. THOMAS, C.E., EDWARDS, P., WICKHAM, T.J., CASTRO, M.G., and LOWENSTEIN, P.R. (2002). Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol. 76, 3452-3460.
43. TIBBLES, L.A., SPURRELL, I.C., BOWEN, G.P., LIU, Q, LAM, M., ZAISS, A.K., ROBBINS, S.M., HOLLENBERG, M.D., WICKHAM, T.J., and MURUVE, D.A. (2002). Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J. Virol. 76, 1559-1568.
44. WONG, M.L., and HSU, M.T. (1988). Psoralen-cross-linking study of the organization of intracellular adenovirus nucleoprotein complexes. J. Virol. 62, 1227-1234.
45. WORGALL, S., WOLFF, G., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.
46. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1, 433-442.
47. ZAISS, A.K., LIU, Q., BOWEN, G.P., WONG, N.C., BARTLETT, J.S., and MURUVE, D.A. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76, 4580-4590.
48. ZHANG, Y., CHIRMULE, N., GAO, G.P., QIAN, R., CROYLE, M., JOSHI, B., TAZELAAR, J., and WILSON, J.M. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707.
49. ZIMMERMAN, G.A., MCINTYRE, T.M., and PRESCOTT, S.M. (1985). Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J. Clin. Invest. 76, 2235-2246.